• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • eyeLEARN
  • Find an Eye Bank
  • Member Login
EBAA

EBAA

We restore sight worldwide

  • Home
  • About
        • About EBAA
        • EBAA is the nationally-recognized accrediting and standards setting body for eye banks.

          • Mission & Vision
          • Board of Directors
          • History
          • Staff
          • Governing Documents
          • Committees
        • View our History Timeline!

  • Members
        • Members
        • We serve our members through a variety of services, resources, education, and much more.

          • Eye Bank Membership
          • Accreditation
          • Paton Society Membership
          • Certification
          • Grants & Scholarships
          • Publications
          • Awards
        • Learn more about the benefits of membership

  • Cornea Donation
        • Cornea Donation
        • Since 1961, EBAA member eye banks have provided tissue for more than 2 million sight restoring, life-changing corneal transplants.

          • Register as a Donor
          • FAQs
          • Regístrese para ser donante
          • What is an eye bank?
          • Common Corneal Diseases
          • The Donation Process
          • Other Uses for Corneas
        • Learn more about the donation process and what eye banks do

  • Events & Observances
  • News & Stories
        • News & Stories
          • Members in the News
          • Recipient Stories
          • Press Releases
          • Donor Stories
        • Share your donation story today!

News & Stories

EBAA Regulatory Alert: Monkeypox

August 29, 2022

EBAA Regulatory Alert:

FDA Releases Important Information for HCT/P Establishments Regarding Monkeypox Virus and HCT/P Donation

August 29, 2022

FDA released a new safety communication for human cells, tissues, or cellular or tissue-based product (HCT/P) establishments regarding monkeypox virus and tissue donation.

There have been no reports of transmission of monkeypox virus through use of HCT/Ps; therefore, the risk of infection transmitted by implantation, transplantation, infusion, or transfer of HCT/Ps remains theoretical. Monkeypox virus nucleic acid has been detected in tissues and secretions of infected humans, such as in skin, semen, and placenta; however, the levels of infectious virus in human cells and tissues have not been well characterized.

Routine measures used to determine donor eligibility are already in place for evaluating risk factors and conditions as well as clinical evidence and physical evidence of infection in HCT/P donors. These safeguards may identify potential donors who are diagnosed with monkeypox virus or who are currently at greatest risk for infection with monkeypox virus. In addition, for cadaveric (non-heart-beating) donors, HCT/P establishments should determine whether an autopsy was not performed due to a perceived risk of transmission of communicable disease or, if an autopsy was performed, whether any special precautions were taken that would suggest there was a special concern over the risk of transmission of a communicable disease from the donor.

Due to the robustness of existing donor screening recommendations, FDA does not recommend using laboratory diagnostic tests to screen HCT/P donors for monkeypox virus.

The HCT/P establishment’s responsible person (21 CFR 1271.3(t)) must determine and document the eligibility of a cell or tissue donor (21 CFR 1271.50). Based on information available at this time, establishments may wish to consider, whether, in the 21 days prior to HCT/P recovery, the donor:

  • was diagnosed with or was suspected of having a monkeypox infection;
  • had close contact with a person or an animal diagnosed with or suspected of having monkeypox infection regardless of the donor’s vaccination status; or
  • developed a rash or other symptoms suggestive of monkeypox infection.

A licensed live replicating virus vaccine indicated for active immunization against smallpox (ACAM2000) may be used against monkeypox under FDA’s Expanded Access Investigational New Drug (IND) mechanism, and recommendations remain applicable in the 2007 Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products related to evaluating an HCT/P donor for receipt of smallpox vaccination in the preceding 8 weeks and screening donors for clinically recognizable vaccinia virus infection from contact with someone who received the live replicating virus smallpox vaccine. The licensed non-replicating virus vaccine indicated for prevention of monkeypox (JYNNEOS) does not carry this same concern.

FDA will continue to monitor cases of monkeypox in the U.S. and worldwide and available information about potential risks of monkeypox virus transmission by HCT/Ps and will provide updates if needed. 

Read more on: Informational Alert

More News & Stories

Celebrating National Minority Donor Awareness Month
August is National Minority Donor Awareness Month. This annual observance is a collaborative initiative of the National (Organ, Eye, and Tissue Donation) Multicultural Action Group (NMAG). As NMAG members, EBAA […]
Informational Alert: Monkeypox and Eye Tissue Donation
September 26, 2022 EBAA continues to closely monitor the outbreak of monkeypox in the United States. The Policy and Position Review Subcommittee (PPRS) of the EBAA Medical Advisory Board has […]

Footer

1101 17th Street NW
Suite 400
Washington DC 20036

phone 202.775.4999
fax 202.429.6036

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter

Connect

  • Contact
  • Share your Story
  • Career Center
  • For the Media
  • Support EBAA

Tools

  • Find an Eye Bank
  • Online Store
  • Advocacy
  • COVID-19 Updates

Our Sites

  • eyeLEARN
  • ONE
  • The Lens
  • eStatIS
  • OARRS

In Partnership

© 2023 EBAA. All Rights Reserved. Disclaimer | Privacy Policy.
EBAA is a 501(c)(3) organization. EIN 72-0678970

A Decrease font size. A Reset font size. A Increase font size.